Unlocking the potential of the microbiome is at the core of Second Genome's drug discovery efforts. Our research and development is focused on applying microbiome science to host biology to discover and develop more effective therapeutic options for patients. 

Our lead candidate, SGM-1019, is a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in IBD. SGM-1019 has completed a Phase I double blind, placebo controlled, single ascending oral dose trial in healthy subjects. SGM-1019 achieved targeted exposure levels and was well tolerated with no significant adverse events. 

We have additional preclinical programs under development in a range of chronic indications.